Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, operational efficiency is key. BeiGene, Ltd. and Geron Corporation, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. BeiGene's SG&A expenses have skyrocketed by over 21,000% from 2014 to 2023, reflecting its aggressive expansion and scaling efforts. In contrast, Geron Corporation's expenses have grown by a modest 312% over the same period, indicating a more conservative approach.

Key Insights

• BeiGene's Growth: Starting at just $6.93 million in 2014, BeiGene's SG&A expenses reached a staggering $1.5 billion by 2023, highlighting its rapid growth strategy.
• Geron's Steady Path: Geron Corporation's expenses increased from $16.76 million in 2014 to $69.14 million in 2023, showcasing a steady, albeit slower, growth trajectory.

These trends offer a fascinating glimpse into the strategic priorities of these biotech firms.